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2003 is a highly celebratory year for genomics,
with the 50th anniversary of the publication of the
double helical structure of DNA (April 1953) and
the announcement of the completion of the human
genome sequence (April 2003). The structure
of DNA, arguably the most important biologi-
cal advance of the 20th century, and the human
genome project have fundamentally affected our
view of biology. The determination of the DNA
structure, in a union of physics, chemistry and biol-
ogy, revealed how information is encoded by genes
and how those genes are replicated; the completion
of the human genome sequence offers the prospect
of disease prediction, prevention and cure, as well
as a deeper understanding of our own evolution.
Having determined the informational content of
many genomes as speciﬁed in the DNA, we are
now moving on to elucidating how gene prod-
ucts function and how the chemistry of life is
translated into complex cellular organization. This
is the area covered by functional genomics, the
exploration of gene function on a global scale.
Functional genomics makes use of revolutionary
technological advances, characteristically capable
of very high sample throughput and producing
vast amounts of data, which require computational
processing for interpretation. Array technologies
have proved particularly powerful. DNA arrays
can reveal genetic variation or monitor expres-
sion of integrated sets or all of the genes of an
organism at the mRNA level in one experiment,
with small samples of tissue; the more recent anti-
body arrays can similarly reveal the protein levels,
while protein or whole-proteome chips give the
opportunity for parallel functional analysis. The
‘classical’ proteomics approaches of high resolu-
tion two-dimensional gel electrophoresis or liq-
uid chromatography, combined with mass spec-
trometry, are capable of separating and identifying
thousands of proteins, revealing changes in pro-
tein expression and the composition of intracel-
lular protein complexes. Protein–protein interac-
tions can be analysed in vivo by the yeast two-
hybrid approach and its derivatives. Antibodies, the
most familiar form of binding molecules, are again
proving their immense value in analysing proteins
of unknown function identiﬁed from the genome
sequence. Elegant knockdown strategies, such as
RNAi or mutagenesis approaches, can speciﬁcally
silence or alter individual genes, the effects of
which can be observed on a global scale in genet-
ically amenable ‘model organisms’ such as yeast,
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nematode, fruit ﬂy and mouse, leading to new phe-
notypes from which gene function may be deduced.
Bioinformatics is a vital growth area without which
the data cannot be made accessible, organized and
understood. The application of these technologies
to the understanding and treatment of human dis-
ease was the focus of this meeting.
What can we expect the beneﬁts of functional
genomics research to be for human health? Taking
cancer as one example, functional genomics tech-
nologies, as exquisitely sensitive high-throughput
tools, allow for improved characterization of the
varieties of types and subtypes of tumours. Tran-
scriptional and protein proﬁling reveal an enor-
mous number of genes that change activity together
as part of an interconnected network. One result
of observing the clusters of genes which change
in expression has been in improving classiﬁca-
tion of cancers, with major clinical signiﬁcance
in assisting earlier diagnosis, prognosis or ther-
apy. As regards drug development, the expecta-
tion is that the human genome information and
functional genomics research will lead to cures
through the identiﬁcation of altered molecular path-
ways, the selection of new tumour-speciﬁc targets
and the development of drugs against each tumour
type. The success of the anti-CML drug Gleevec
(and others in the wake of this) suggests that
the ‘designer drugs’ approach will deliver. How-
ever, given the number of cancer varieties, the
huge cost of drug development and many years
of clinical testing and validation, this cannot typi-
cally be expected to occur very quickly. A realis-
tic short-term goal for functional genomics, which
will increase survival, is improved early diagno-
sis, currently lacking for many cancers, through the
discovery of protein markers in body ﬂuids, partic-
ularly serum. In particular, proteomics technologies
of mass spectrometry and antibody arrays offer the
possibility of screening for early disease. Improved
diagnostic methods for early disease detection are
probably where the promise of functional genomics
will be realized most rapidly.
A major potential beneﬁt of genome information
is prevention of disease by identifying susceptible
individuals through their genomic proﬁle, correlat-
ing DNA sequence variation (SNPs, haplotypes)
with disease susceptibility. While the power of pre-
diction for single gene disorders conferred by the
sequence is very good, it is currently much more
modest for the common, multifactorial diseases,
for which the phenotypes are likely to be caused
by combinations of alleles. Functional genomics
approaches may allow us to understand how the
interactions among gene products ultimately give
rise to phenotypes of complex diseases. However,
this will be very challenging and many components
will have to be integrated to understand how the
disease phenotypes are generated.
Genomic research and its implications have
raised a range of issues for ethical and legal consid-
eration. Health predictions and early detection are
clearly of value where treatment or lifestyle modiﬁ-
cation are effective, but where there is little or noth-
ing to be done the information may well produce
major stress for the individual and may adversely
impact life insurance or employment. What should
be revealed and how the information is obtained
and used are becoming important considerations.
Population-based collections of tissues and medical
histories are invaluable resources for genomics but
raise questions of the rights of the individual and of
the researchers, as well as the interests of compa-
nies keen to utilize the information in drug devel-
opment. On the commercial front, there are valid
concerns over patenting of genome information and
its commercial exploitation. To be of beneﬁt to
society, the results of genomics research require
commercial development by biotech and pharma-
ceutical companies, and it is clearly in the ﬁnancial
interests of universities and institutions to facilitate
technology transfer. The problem is how to recon-
cile the academic and industrial ethos — sharing
of results versus conﬁdentiality and patent rights.
The results of publicly funded research should be
made freely available for the good of society, as
has happened with the human genome project, but
the commercial sector cannot operate in quite the
same way. While academic researchers should not
be restricted in what they can do and publish, at
the same time there has to be an easy transition
into patenting, commercial application and devel-
opment where different rules apply. Problems such
as these will have to be addressed to achieve the
widely anticipated beneﬁts of the understanding of
the human genome in this 50th anniversary year
of DNA.
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